A Multicenter Study to Estimate the Prevalence of HER2 low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice among Unresectable and/or Metastatic Breast Cancer Patients with HER2-low Status – the RetroBC-HER2L Study
18 Years - 130 Years
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 May 2022 by AstraZeneca
No locations available
Patients with confirmed diagnosis of HER2-neg, unresectable and/or mBC regardless of hormone status dating back from 31 December 2017 - but no older than 01 January 2015 - who progressed on any systematic anti-cancer therapy will be involved in this study.